Induction of neutralizing antibodies by a tobacco chloroplast-derived vaccine based on a B cell epitope from canine parvovirus  by Molina, Andrea et al.
www.elsevier.com/locate/yviroVirology 342 (20Induction of neutralizing antibodies by a tobacco chloroplast-derived
vaccine based on a B cell epitope from canine parvovirus
Andrea Molinaa, Jon Veramendia,*, Sandra Herva´s-Stubbsb,1
aInstituto de Agrobiotecnologı´a, Universidad Pu´blica de Navarra-CSIC, Campus Arrosadı´a, 31006 Pamplona, Spain
bDepartamento de Ciencias de la Salud, Universidad Pu´blica de Navarra, Campus Arrosadı´a, 31006 Pamplona, Spain
Received 31 May 2005; returned to author for revision 14 July 2005; accepted 9 August 2005
Available online 2 September 2005Abstract
The 2L21 epitope of the VP2 protein from the canine parvovirus (CPV), fused to the cholera toxin B subunit (CTB-2L21), was expressed
in transgenic tobacco chloroplasts. Mice and rabbits that received protein-enriched leaf extracts by parenteral route produced high titers of
anti-2L21 antibodies able to recognize the VP2 protein. Rabbit sera were able to neutralize CPV in an in vitro infection assay with an efficacy
similar to the anti-2L21 neutralizing monoclonal antibody 3C9. Anti-2L21 IgG and seric IgA antibodies were elicited when mice were
gavaged with a suspension of pulverized tissues from CTB-2L21 transformed plants. Combined immunization (a single parenteral injection
followed by oral boosters) shows that oral boosters help to maintain the anti-2L21 IgG response induced after a single injection, whereas
parenteral administration of the antigen primes the subsequent oral boosters by promoting the induction of anti-2L21 seric IgA antibodies.
Despite the induced humoral response, antibodies elicited by oral delivery did not show neutralizing capacity in the in vitro assay. The high
yield of the fusion protein permits the preparation of a high number of vaccine doses from a single plant and makes feasible the oral
vaccination using a small amount of crude plant material. However, a big effort has still to be done to enhance the protective efficacy of
subunit vaccines by the oral route.
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Traditional vaccines consist of either attenuated or
inactivated microorganisms delivered by injection. Despite
the low-virulence of the strain used, attenuated vaccines can
cause severe diseases in immunodeficient individuals, and
inactivated vaccines can still harbor toxins that compromise
their safety. These problems can be circumvented by subunit
vaccines. The advance in molecular biology techniques has
allowed the cloning of relevant antigenic sequences from
pathogens into less dangerous hosts, where they are
expressed and purified for immunization. However, the
production of subunit vaccines in microorganisms and0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Pasteur. 25, Rue du Dr. Roux, 75724, Paris, France.mammalian cell systems is expensive and needs stringent
purification processes. The development of plant biotech-
nology has made possible the use of transgenic plants as an
alternative to cell-cultured-based subunit vaccines. The
culture of plants is fairly cheap and can be scaled up with
a low cost in relation to fermentation processes. In addition
to the safety of subunit vaccines, plant-based vaccines are
much less likely to harbor pathogenic microbes than are
mammalian cell-based vaccines. Although antigens can be
purified for injection from cellular cultures and plants,
edible plants offer an oral delivery system that would avoid
the costly purification processes needed for injectable
vaccines (Walmsley and Arntzen, 2000).
Many different subunit vaccines have been expressed in
nuclear transgenic plants, and most of them have been
reported to be immunogenic by oral delivery in humans or
animal models (Arakawa et al., 1998; Streatfield et al.,
2001; Tacket et al., 1998, 2000; Wigdorovitz et al., 1999).05) 266 – 275
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shown to be protective. An important limitation of oral
subunit vaccines relies on the digestive system that could
degrade the protecting antigens and rest efficacy to the
vaccine. Antigens expressed in plants are ‘‘bioencapsulated’’
within cell walls and membrane compartments in such a
way that they may survive better the gastric passage and
reach the intestine, which is rich in immune cells (Liu, 1999;
Walmsley and Arntzen, 2000). However, a key limitation of
nuclear transgenic plants is the low expression level of
antigens that oblige to use large amounts of plant material to
get the right dose of administration. An alternative to
improve the antigen expression level in plants is chloroplast
transformation. Several recombinant proteins have been
expressed by chloroplast transformation resulting in the
accumulation of large quantities of recombinant products,
up to 46% of total soluble protein (TSP) (De Cosa et al.,
2001). The high expression of foreign genes in the
chloroplast is attributed to the high-copy number of the
transgene (up to 10,000/cell), lack of gene silencing and
higher stability of the protein in the stroma of the
chloroplast. Other additional advantage of this technique
is the maternal inheritance of plastids that avoid transgene
escape through the pollen (Bock, 2001). To date, only a few
subunit antigens have been expressed in chloroplasts and
have been evaluated for specific immunogenic response.
Tregoning et al. (2003, 2005) reported the expression of a
non-toxic fragment of tetanus toxin and showed the
induction of specific antibodies against tetanus by nasal
and oral routes. A protective antigen against anthrax was
expressed in tobacco chloroplasts and showed its efficacy
by in vitro assays (Watson et al., 2004).
Canine parvovirus (CPV) is a widespread virus that
causes acute gastroenteritis and myocarditis in dogs. CPV is
a non-enveloped single-stranded DNA virus with a capsid
formed by several proteins: VP1, VP2 and VP3. VP2 is far
more abundant than the other two components. The 2L21
peptide (21 amino acids in length) is a B-cell epitope and
corresponds to the amino terminus of the VP2 protein. This
peptide behaves as a hapten, its coupling being necessary to
a carrier protein to induce a humoral response (Langeveld et
al., 1994b). The 2L21 peptide coupled to KLH has provided
protection against the virus in dogs (Langeveld et al.,
1994b). This peptide was previously expressed in two plant
viruses, the cowpea mosaic virus (Dalsgaard et al., 1997)
and the plum pox potyvirus (Fernandez-Fernandez et al.,
1998), and as an amino terminal fusion with h-glucuroni-
dase (GUS) in Arabidopsis by nuclear transformation (Gil
et al., 2001).
In a previous work (Molina et al., 2004), we have
reported the expression of a chimeric protein consisting of
the cholera toxin B subunit (CTB) bearing at the C-terminus
the 2L21 epitope in tobacco chloroplasts (CTB-2L21). CTB
is described as an adjuvant for oral immune response. CTB
may facilitate antigen delivery and presentation to the gut
associated lymphoid tissues (GALT) due to its affinity to thecell surface receptor GM1-ganglioside located on cells of the
GALT (Arakawa et al., 1998). The chimeric protein was
expressed at high levels in mature plants (up to 31% TSP),
and the 2L21 epitope was correctly exposed at the C-
terminus of the fusion protein without affecting pentameri-
zation and GM1-ganglioside binding of CTB molecule.
In the present work, we performed parenteral, oral and
combined (parenteral plus oral boosters) immunizations by
using leaf extracts or pulverized tissues from CTB-2L21
transformed plants. Parenteral immunization with leaf
extracts induced high titers of antibodies against 2L21 and
VP2 in mice and rabbits. Rabbit sera showed a similar
neutralizing activity than the anti-2L21 neutralizing mono-
clonal antibody 3C9 in an in vitro infection assay. Only
pulverized tissues were able to induce anti-2L21 IgG and
seric IgA antibodies when delivered by oral route. Finally,
oral boosters helped to maintain the anti-2L21 IgG response
induced after a single injection, whereas parenteral admin-
istration of the antigen primed the subsequent oral boosters
allowing the induction of anti-2L21 seric IgA antibodies.Results
Humoral response induced by i.p. injection of plant-derived
2L21-expressing immunogens
In order to study the immunogenicity of chloroplast-
expressed immunogens containing the 2L21 epitope, mice
were i.p. immunized with crude or protein-enriched leaf
extracts from CTB-2L21 or green fluorescent protein (GFP)
fused to the 2L21 epitope (GFP-2L21). Anti-2L21 anti-
bodies were only detected in the groups that received CTB-
2L21 recombinant protein (Fig. 1A). Titers of antibodies
increased with consecutive immunizations. The highest
antibody titers were observed in the group immunized with
CTB-2L21-enriched extracts. Mice immunized with GFP-
2L21-enriched extracts showed a marginal titer of 12. The
groups that received the synthetic 2L21 peptide and the
crude leaf extracts from GFP-2L21-transformed and non-
transformed plants did not elicit anti-2L21 antibodies. No
antibodies (titer < 10) were detected in any group against the
pre-S2 control peptide (data not shown). The lack of
response found in groups immunized with GFP-2L21 leaf
extracts could be due to the fact that the 2L21 epitope is not
correctly presented at the C-terminus of GFP or that GFP
does not work efficiently as an immunological carrier.
The antibodies elicited with CTB-2L21 also recognized
the VP2 protein (Fig. 1B). The highest anti-VP2 titers were
found in the group immunized with CTB-2L21-enriched
extracts. Sera from mice immunized with GFP-2L21-crude
or -enriched extracts, 2L21 synthetic peptide or leaf extracts
from non-transformed plants did not recognize the VP2
protein (data not shown). To confirm that VP2 recognition
by sera elicited with CTB-2L21 was due to the humoral
response induced against the genetically coupled 2L21
Fig. 1. Humoral response induced by i.p. injection of plant-derived 2L21 expressing immunogens. (A, B) Mice were i.p. immunized with protein-enriched
extract (filled symbols) or crude (open symbols) extracts from CTB-2L21 (circles) or GFP-2L21 (squares) transformed plants. As control, mice were i.p.
immunized with synthetic 2L21 peptide (filled triangle) or with leaf extract from a non-transformed plant (asterisk). Pooled sera were titrated against 2L21
peptide (A). Sera that recognized 2L21 peptide were also titrated against VP2 protein (B). (C) Anti-VP2 competitive ELISA. Pooled sera (day 50) from mice
immunized with protein-enriched (filled symbols) or crude (open symbols) CTB-2L21 extracts were diluted at equivalent dilution for the recognition of 2L21
epitope (1/1000 and 1/70, respectively). The diluted sera were incubated with serial dilutions of soluble 2L21 peptide (circles) or non-transformed leaf extracts
(squares) and then titrated against VP2 protein. (D) Time course of IgG isotypes after immunization with CTB-2L21-enriched (filled symbols) or -crude (open
symbols) extracts; IgG1 (circles), IgG2a (squares). (A–D) Data are presented as the means and standard errors (n = 2–4). (E) Western blot analysis of the
humoral response. Bacterial CTB (1 Ag), CTB-2L21-crude (CTBc) and CTB-2L21-enriched (CTBen) extracts and leaf extracts from non-transformed plants
(WT) were resolved on a 10% SDS-PAGE gel under reducing conditions. Sera were tested at equivalent dilutions for the recognition of 2L21 epitope. The
amount of total soluble protein loaded in each lane was selected to get a similar blot intensity corresponding to the monomer CTB-2L21 band. Oligomers of
CTB-2L21 are marked with arrowheads (M—monomer, D—dimer, T—trimer). One representative experiment out of two is shown.
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soluble 2L21 peptide or crude extracts from non-trans-
formed leaves and then incubated with the immobilized VP2
protein. Fig. 1C shows that recognition of VP2 protein was
inhibited by soluble 2L21 peptide, but not by non-trans-
formed leaf extracts, confirming that recognition of VP2
protein is 2L21 epitope-specific. At the equivalent dilutions
tested (1/1000 and 1/70 for serum elicited with CTB-2L21-
enriched and -crude extracts, respectively), both sera
showed similar IC50.
In order to know the IgG isotype profile induced after
priming and boosting with CTB-2L21, IgG1 and IgG2a
isotypes were determined. Fig. 1D shows the presence of
both isotypes, IgG1 being the predominant one. Other
authors (Freytag and Clements, 2005; Tregoning et al.,2005; Webster et al., 2005) observed the same behavior
using CT or CTB as adjuvant. To further characterize the
humoral response, crude and protein-enriched leaf extracts
from transgenic plants were resolved by electrophoresis
and hybridized with sera elicited with CTB-2L21-enriched
or -crude extracts. Sera were tested at equivalent dilutions
for the recognition of 2L21 epitope. Both sera recognized
the different CTB-2L21 oligomers (Fig. 1E). As expected,
the immune response was not restricted to the 2L21-
expressing immunogens. Antibodies against CTB and also
against other proteins from the leaf extracts were elicited.
At equivalent dilution of sera, recognition of plant
proteins by sera elicited with CTB-2L21-enriched extracts
was much lower than by sera elicited with the crude
extracts.
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administration of plant-derived CTB-2L21
In order to study the neutralizing capacities of the
humoral response induced by systemic administration of
CTB-2L21 expressed in chloroplasts, two rabbits were
immunized with CTB-2L21-enriched extracts as described
in Materials and methods. High titers of anti-2L21
antibodies were induced being able to recognize the VP2
protein (Fig. 2A). To test the in vitro CPV neutralizing
activity of these antibodies, several dilutions of the serum
corresponding to the highest titer (day 53) were pre-
incubated with CPV and then seeded on CRFK cells. The
antibodies induced in rabbits by CTB-2L21 efficiently
neutralized CPV infection of CRFK cells (Fig. 2B).
Preimmune sera tested at 1/10 dilution failed to neutralize
the virus. The neutralizing activity of the rabbit serum and
the 2L21 epitope-specific mAb 3C9 were compared. When
the sera were assayed at the dilution corresponding to their
titer (1/1080 for rabbit serum; 1/2I106 for mAb 3C9), both
sera showed similar neutralizing activity (Fig. 2B). Rabbit
sera collected on days 74 and 81 showed equivalent
neutralizing capacity to the serum from day 53 (data not
shown).
Humoral response induced by oral administration of
plant-derived CTB-2L21
To study the immunogenicity of chloroplast-expressed
CTB-2L21 after oral administration, mice were gavaged
with CTB-2L21-enriched extracts. Mice received a dose of
extracts containing 200 or 1000 Ag of CTB-2L21 protein.
Only a marginal IgG response was detected in the group thatFig. 2. Neutralizing capacity of the anti-2L21 humoral response induced with the pl
after immunization with CTB-2L21-enriched extracts given in Freund’s adjuvant. R
extracts containing 500 Ag of recombinant protein and boosted with the same im
Antibody titers against 2L21 peptide (filled triangles) and VP2 protein (open tria
response induced in rabbits. Data are presented as the means and standard errors
gray bars), the mAb 3C9 (dark gray bars) and the preimmune serum (dilution
monolayer. Cells were fixed 3 days later, and the presence of virus was detected w
counted, and neutralization percentages were calculated. Additionally, sera were
neutralization percentage).received 1000 Ag of CTB-2L21 (Fig. 3A). No anti-2L21
immune responses were detected after oral administration of
CTB-2L21-crude extracts (data not shown). When the
antigen is delivered as soluble leaf extract, the enzymes
from the digestive system may have easy access to the
antigen and rest efficacy to the oral vaccine. A way to
reduce the antigen gastric digestion could be the delivery of
the antigen as leaf pieces instead of leaf extracts. All our
efforts to feed mice with tobacco leaves were null. To
simulate the ingestion of leaf pieces, mice were gavaged
with a PBS suspension of pulverized leaf tissue. Anti-2L21
IgG antibodies were detected after the second administration
of the tissue suspension (day 35). The titer of antibodies
increased after the third immunization (day 50) and was
maintained after the fourth (day 75) (Fig. 3A).
To test the effect of combined immunization, mice
received a single i.p. injection of CTB-2L21-enriched
extracts and repetitive oral boosters with the same extract
preparation or with a CTB-2L21-tissue suspension. As
control, a group of mice received only a single i.p. injection
of CTB-2L21-enriched extract. A weak humoral response
was detected after the i.p. injection (Fig. 3B). This response
declined in the group immunized only i.p., but it was
maintained in the groups that received the oral boosters. At
day 130 from the parenteral injection, anti-2L21 IgG titers
were 10-fold higher in the groups that received combined
immunization in comparison to the group that only received
one i.p. injection. Similar titers of IgG antibodies were
elicited after oral boosters with CTB-2L21-enriched extracts
and CTB-2L21-tissue suspensions (Fig. 3B). Titers of
antibodies elicited by oral and combined administration of
CTB-2L21-tissues were similar (Fig. 3A, B). Anti-2L21 IgG
antibodies induced after oral and combined administrationant extracts expressing CTB-2L21. (A) Humoral response induced in rabbits
abbits were primed by an intradermic injection (i.d.) of CTB-2L21-enriched
munogen on days 21 and 42 (i.d.) and on days 63 and 64 (subcutaneous).
ngles) are shown. (B) In vitro CPV neutralizing activity of the anti-2L21
of 5 independent assays. Serial dilutions of the rabbit serum (day 53) (light
10, black bar) were pre-incubated with CPV and then seeded on CRFK
ith mAb 3C9 and FITC-conjugated anti-mouse IgG. Fluorescent cells were
assayed at the dilution corresponding to their titer (filled circle) (dilution,
Fig. 3. Humoral response induced by oral or combined immunization of plant-derived 2L21-expressing immunogens. (A) 2L21-specific IgG antibodies
induced after oral immunization. Mice were immunized by oral administration of CTB-2L21-enriched extracts (circles) containing 200 Ag (open circles) or
1000 Ag (filled circles) of recombinant protein and with a CTB-2L21-tissue suspension (squares; 600 Ag of CTB-2L21). Animals were boosted by oral route at
days 21, 35 and 50. (B) 2L21-specific IgG antibodies induced after combined immunization. Mice received a single i.p. injection of CTB-2L21-enriched
extracts in CFA at day15 and repetitive oral boosters at days 0, 21, 35 and 50. The antigen preparations and doses of CTB-2L21 protein used in the oral
boosters were the same than in (A). As control, a group of mice only received a single injection of CTB-2L21-enriched extracts in CFA (diamonds). (C)
Recognition of VP2 protein by sera (day 75) from responder groups in (A, B). IP: one single i.p. injection. OrCTBtis: oral immunizations with CTB-2L21-
tissues. CoCTBtis: a single i.p. injection plus oral boosters with CTB-2L21-tissues. CoCTBen200 and CoCTBen1000: a single i.p. injection plus oral boosters
with CTB-2L21-enriched extracts (200 and 1000 Ag of CTB-2L21, respectively). (D) 2L21-specific IgA antibodies in sera from responder groups in (A, B).
Legends of x axis as in (C). Data are presented as the means and standard error (n = 3–6).
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the VP2 protein (Fig. 3C).
Anti-2L21 IgA antibodies were detected in the sera
elicited by oral and combined administration of CTB-
2L21-tissues, the amount of specific IgA being similar in
both groups (Fig. 3D). No seric IgA antibodies were
detected after oral delivery of protein-enriched extracts
(data not shown). However, combined administration of
CTB-2L21-enriched extracts (1000 Ag of protein) induced
detectable amount of anti-2L21 IgA antibodies in sera
(Fig. 3D). Seric IgA levels were maintained up to 115 days
after the first immunization. Anti-2L21 IgA were never
detected in saliva (data not shown). Despite that combined
immunization (parenteral + oral) renders CTB-2L21
immunogenic, sera elicited by the oral route were not able
to neutralize CPV in the in vitro neutralization assay (data
not shown).Discussion
Plants are a safe and cheap production system for
proteins of pharmaceutical interest including vaccines
(Daniell et al., 2001). The high yield of antigens expressed
in plant chloroplasts not only would make the progress of
oral vaccines easy, but also the development of purified
plant-based vaccines which could be applied by parenteral
route.
In this work, we have developed a partially purified
animal vaccine based on the 2L21 epitope fused to CTB
and expressed in chloroplast-transformed plants. Enrich-
ment of CTB-2L21 leaf extracts was performed by
standard ammonium sulfate precipitation. Precipitation
with ammonium sulfate is a non-specific way to enrich
the amount of proteins in a sample and does not exclude
coprecipitation of other irrelevant proteins present in the
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sulfate precipitation are acceptable for developing animal
vaccines (Martinez et al., 1992). Precipitation with
ammonium sulfate enriched the concentration of CTB-
2L21 in the extract of plants more than 15 times and also
increased the purity of this antigen. We have estimated that
a single chloroplast transgenic plant yields 310 mg of
CTB-2L21 (Molina et al., 2004). Although recombinant
protein losses in the purification process were 40%, we
could obtain 370 vaccine units (assuming a dose of 500
Ag) from a single plant. This high yield suggests that
purified plant-based vaccine production by using chlor-
oplast transformation could be technically feasible for
commercial purposes.
Previously, we showed that i.p. immunization of mice
with crude leaf extracts from CTB-2L21 chloroplast trans-
genic plants elicits antibodies able to recognize the VP2
protein (Molina et al., 2004). In the present study, we
confirm these results and show that partially purified
chloroplast-expressed CTB-2L21 induces higher titers of
anti-2L21 antibodies than the same dose of antigen given as
crude extract.
Western blot analyses showed that antibodies against
plant proteins and the CTB carrier were also induced with
both CTB-2L21 protein-enriched and crude leaf extracts
(Fig. 1E). The humoral response against plant proteins was
much lower when the immunogen used was protein-
enriched leaf extracts. A simple explanation for this
observation could be that the antigen is masked when a
high number of plant proteins are present, by being
sequestered or simply physically hidden. Partial purifica-
tion enriches the plant extracts in CTB-2L21 and may
facilitate its recognition by anti-2L21-specific B lympho-
cytes. Despite the very high polyclonal humoral response
obtained from immunized mice, recognition of VP2 protein
was shown to be specific of the induced anti-2L21
antibodies since only soluble 2L21 peptide, but not soluble
proteins from non-transformed leaf extracts, could inhibit
recognition of immobilized VP2 protein in a competitive
ELISA (Fig. 1C).
CTB-2L21-enriched preparations were also highly
immunogenic in rabbits. Rabbit sera, elicited by parenteral
injection of CTB-2L21-enriched extracts, were able to
neutralize CPV and prevented in vitro infection of CFRK
cells (Fig. 2B). Similar results were observed with mice sera
(data not shown). At the dilution corresponding to their
titers, rabbit sera showed equivalent neutralizing activity to
the anti-2L21 neutralizing mAb 3C9. Previous works have
shown that the in vitro neutralizing activity of rabbit sera
elicited with peptides comprising the 2L21 epitope fused to
KLH (Langeveld et al., 1994a) correlates with protection
against CPV challenge in dogs vaccinated with the same
immunogens (Langeveld et al., 1994b). Therefore, it is
expected that parenteral immunization with CTB-2L21-
enriched extracts will also provide protection against CPV
infection in the target animal.Although vaccine antigens could be readily purified from
the plant tissue for injection, edible plants offer the
advantage of oral delivery system, avoiding the costly
purification process required for injectable vaccines.
Besides, chloroplast transformation would reduce signifi-
cantly the amount of plant material required per immuno-
genic dose (i.e. 70 mg for 500 Ag of recombinant protein, in
the present study). This could be an important limitation of
antigens expressed in nuclear transgenic plants. Due to the
low expression levels, immunogenic doses cannot be
delivered in a reasonably small mass. In consequence, the
ingestion of large amount of raw plant tissues could cause,
in some instances, side effects, such as vomiting, diarrhea
and fever (Tacket, 2005).
In this work, we also studied the immunogenicity by
oral route of CTB-2L21 recombinant protein expressed in
chloroplast-transformed tobacco plants. Although tobacco
is not the ideal plant for oral application, it is widely
employed for research and proof-of-concept studies. Up to
now, tobacco is the only crop plant where chloroplast
transformation is routine (Maliga and Graham, 2004).
However, recent results on tomato and carrot plastid
transformation (Kumar et al., 2004; Ruf et al., 2001)
augur a promising future of edible chloroplast transgenic
plants for vaccination purposes. Our data show that low
but significant titers of anti-2L21 IgG and seric IgA
antibodies are elicited when mice are gavaged with a
suspension of pulverized tissues from CTB-2L21 trans-
formed plants but not with CTB-2L21-enriched extracts
(Fig. 3A, D and data not shown). Crude leaf extracts,
administered by oral route, were unable to develop an
immune response (data not shown). It can be expected that
the sturdy plant cell walls provide antigen protection from
degradation in the gut. To confirm this hypothesis,
additional experiments with enteric capsules could be
performed. If antigens given orally were partially degraded
in the gut, the capsule protection would enhance the
immune response. The higher immunogenicity of the
pulverized tissue suspension in comparison with the
soluble antigen extract could be due to a lower degrada-
tion of the recombinant protein when it was administered
in the protective environment of the plant tissues (Tacket,
2005).
Gil et al. (2001) expressed the 2L21 epitope fused to the
amino terminus of GUS protein in Arabidopsis plants by
nuclear transformation. The expression of the fusion protein
described by these authors was 10-fold lower (3% TSP) than
in transgenic tobacco chloroplasts (31% TSP) (Molina et al.,
2004). Using crude leaf extracts containing a comparable
dose of recombinant protein, equivalent humoral response
was obtained after i.p. and oral administration to the one
described in the present work.
We examined other possibilities for oral immunization. It
has been reported that parenteral administration of the
antigen primed the subsequent oral booster immunizations
by increasing mucosal and systemic immune responses
Fig. 4. Schematic representation of the chloroplast transformation vectors
for expression of antigenic proteins containing the 2L21 epitope. The DNA
region inserted in the chloroplast genome by homologous recombination
contains the aminoglycoside 3V-adenylyltransferase (Spec) gene, which
confers spectinomycin resistance, the promoter and 5VUTR (PpsbA) and
terminator (TpsbA) of the plastid psbA gene and the B subunit of the
cholera toxin (CTB) or green fluorescent protein (GFP) fused to the 2L21
epitope.
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results are in agreement with these previous observations.
We show that oral boosters with CTB-2L21-enriched
extracts help to maintain the IgG response induced after a
single i.p. injection of the same immunogen preparation,
although the titers of antibodies were quite low. Moreover,
previous activation of the immune system by parenteral
route followed by oral boosters resulted in low but
significant levels of seric IgA in the groups gavaged with
the higher dose of CTB-2L21-enriched extracts. The
induction of seric IgA may reflect also the stimulation of
a mucosal anti-2L21 response, although we were unable to
detect IgA in saliva. The mechanism underlying the
increased mucosal responsiveness of parenterally primed
animals to orally delivered antigens is not clear yet but
could be related to an enhanced capability of the systemi-
cally primed immune system to react to small quantities of
antigen entering the body by mucosal routes. This concept
of parenteral priming followed by oral boosters is of great
interest because it could be a good way to simplify
vaccination protocols and also to recall immune responses
to ensure a good level of protection.
Unexpectedly, the IgG and IgA responses induced by oral
delivery of pulverized tissues were scarcely affected by a
previous parenteral injection of CTB-2L21-enriched extracts.
Moreover, we have observed that the maximum amount of
anti-2L21 IgG and seric IgA antibodies detected in all
responder groups was always similar, independently of the
antigen dose employed (200–1000 Ag/mouse), the antigen
form used for oral administration (leaf extracts or pulverized
tissues) and the protocol followed (combined or only oral
administration). To sum up, humoral response elicited by oral
delivery of chloroplast-expressed CTB-2L21 was, although
detectable, very weak and did not show neutralizing capacity
in the in vitro assay (data not shown). Several factors could be
limiting the efficacy of the oral immunization such as
degradation of the antigen, induction of tolerance, etc.
Apparently we are not inducing tolerance in our system since
a similar immune response was observed after i.p. immuni-
zation with CTB-2L21-crude extracts in naive mice and in
mice that received previously three oral boosters of CTB-
2L21-crude extracts (200 Ag/dose) (unpublished observa-
tions). Another important point to take into account is the
capacity of specialized intestinal epithelial cells to uptake
antigens. M cells located in the Peyer’s patches selectively
take up particulate antigens, such as virus particles, while the
majority of subunits antigens in the intestine are ignored by
the immune system (Ogra et al., 2001). AlthoughCTB has the
capacity to bind to GM1-ganglioside receptors on the
intestinal epithelial cells (Svennerholm, 1976), there is no
direct evidence that this binding will enhance neither the
uptake nor the presentation of CTB-based vaccines (Freytag
and Clements, 2005). The targeting of plant-derived antigens
to M cells is an important area of research that could be of
great interest to explore in order to enhance the immunoge-
nicity of oral plant-based vaccines.In summary, our data indicate that chloroplast-trans-
formed plants can be a profitable and commercial source of
purified antigens for injectable vaccines. Enriched CTB-
2L21 leaf extracts could be an attractive alternative for
parenteral vaccination of dogs. Oral delivery of plant-
derived CTB-2L21, although subjected to further improve-
ment, could be useful to induce or to boost systemic and
mucosal immune responses against CPV.Materials and methods
Plant expression vector construction and plant
transformation
Chloroplast transformation vectors, containing the 2L21
peptide, and plants used in this work were previously
described (Molina et al., 2004). Schematic constructions for
tobacco transformation are shown in Fig. 4.
Mice
Female 8-week-old BALB/c mice were purchased from
IFFA Credo (Barcelona, Spain). They were hosted in
appropriate animal care facilities and handled following
institutional guidelines.
Antigen, peptides and monoclonal antibody against VP2
VP2 used was a baculovirus-expressed recombinant
protein (Ingenasa, Madrid, Spain). The 2L21 peptide
(MSDGAVQPDGGQPAVRNERATG) and the control pep-
tide WNSTAFHQTLQDPR (amino acids 122–135 of the
pre-S2 region of the hepatitis B virus surface antigen) were
synthesized by Bioworld (Dublin, Ohio, USA). The 3C9
mAb anti-2L21 was from Ingenasa (Madrid, Spain) (Lopez
de Turiso et al., 1991). Purified bacterial CTB was from
Sigma.
Preparation of leaf extracts, pulverized tissues and partial
purification of immunogens
Leaves from transformed and non-transformed plants
were ground in liquid nitrogen and homogenized in 2–3
Table 1
Oral immunization experiments with CTB-2L21
Immunization type Extracts Dose (Ag) Group name
Oral Enriched extract 200 OrCTBen200
1000 OrCTBen1000
Pulverized tissue 600 OrCTBtis
Combined
(single i.p.
injection +
oral boosters)
Enriched extract 200 CoCTBen200
1000 CoCTBen1000
Pulverized tissue 600 CoCTBtis
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steps were performed on ice or at 4 -C. Tissue homogenates
were centrifuged to remove cellular debris yielding the
crude leaf extracts (CTB-2L21-crude). Partial purification of
leaf extracts was performed by ammonium sulfate precip-
itation (40–80%). Precipitated proteins were resuspended in
PBS, yielding the protein-enriched leaf extract (CTB-2L21-
enriched). Crude and protein-enriched leaf extracts were
stored at 80 -C until they were used.
Leaves from CTB-2L21 transformed plants were ground
in liquid nitrogen obtaining the pulverized tissue (CTB-
2L21-tissue) that was stored at 80 -C until use. The total
protein content of extracts was measured by Bradford assay
(Bio-Rad). The amount of recombinant protein in pulverized
tissues and leaf extracts was determined by ELISA as
previously described (Molina et al., 2004).
Immunization of animals
Parenteral immunization
To study the immunogenicity of chloroplast-expressed
immunogens containing the 2L21 epitope, mice were intra-
peritoneally (i.p.) immunized with either crude or protein-
enriched leaf extracts from either CTB-2L21 or GFP-2L21
transformed plants, resulting to 4 groups (n = 5–7) of
immunization. Each mouse within a group received 20 Ag of
the corresponding 2L21 recombinant protein. The amount of
total protein extract ranged from 150 to 250 Ag. Control mice
were i.p. immunized with synthetic 2L21 peptide (100 Ag of
peptide) diluted in PBS or with crude leaf extract from a non-
transformed plant (250 Ag of total protein extract). The
peptide and the different plant extract preparations were
administered in Complete Freund’s Adjuvant (CFA). Sub-
sequently, mice were boosted at days 21 and 35 with the
extracts emulsified in Incomplete Freund’s Adjuvant (IFA).
Blood was collected from retro-orbital plexus at days 0, 21,
35, 50 and 90.
For immunization of rabbits, two animals (Charles River,
Barcelona) were immunized by intradermic injection (i.d.)
with CTB-2L21-enriched extracts containing 500 Ag of
recombinant protein in CFA. Rabbits were boosted i.d. on
days 21 and 42 and subcutaneously on days 63 and 64 with
the same dose of antigen in IFA. Blood was collected from
the medium artery on days 21, 42, 53, 74 and by cardiac
puncture on day 81.
Oral immunization
A summary of oral immunization experiments is shown
in Table 1. Mice (n = 6) were gavaged with CTB-2L21-
enriched extracts (200 or 1000 Ag of CTB-2L21) or with a
CTB-2L21-tissue suspension containing 600 Ag of the
recombinant protein. Pulverized tissue was resuspended in
PBS for oral administration (50 mg tissue/100 Al PBS).
Mice were orally boosted with the same dose and
preparation of antigens at days 21, 35 and 50. Blood and
saliva were collected at days 0, 21, 35, 50, 75 and 115.Combined immunization
Mice were immunized (day15) by a single i.p. injection
of CTB-2L21-enriched extracts (20 Ag of CTB-2L21) in
CFA and repetitive oral boosters (days 0, 21, 35 and 50) with
the same preparation (200 or 1000 Ag of CTB-2L21) or with
a CTB-2L21-tissue suspension (600 Ag of CTB-2L21). As
control, a group of mice received only a single injection of
CTB-2L21-enriched extracts in CFA. Blood and saliva were
collected at days 15, 0, 21, 35, 50, 75 and 115.
Collected blood was centrifuged (16,600g) to separate
the serum from the cellular fraction. Sera and saliva were
stored at 80 -C until use.
Determination of the humoral response
Titration of anti-sera against the 2L21 epitope was carried
out by an in-house ELISA test. Briefly, 96-well microtiter
plates (Costar, USA) were coated by overnight incubation at
4 -C with 50 Al of 2L21 peptide (1 Ag/well), control peptide
(1 Ag/well) or VP2 (0.1 Ag/well) diluted on 100 mM
carbonate buffer (pH 9.6). Subsequently, wells were blocked
(1 h at room temperature) with PBS (pH 7.4) containing
Tween-20 (0.1%) and skimmed milk (1%) (PBSMT) and
then incubated (1 h, 37 -C) with serial dilutions of pooled
sera in PBSMT (beginning for 1/10 dilution, in the case of
sera from mice immunized by i.p. route, and 1/4 for those
sera from mice immunized by oral route). Then, plates were
incubated (1 h, 37 -C) with biotinylated goat anti-mouse IgG
antibody (Amersham) and next with streptavidin–horse-
radish peroxidase conjugate (Amersham) (1 h, 37 -C).
Washes were performed between each step with PBS (pH
7.4) containing Tween-20 (0.1%). Color was developed by
adding ABTS [2, 2V-azino-bis (3-ethylbenzthiazoline-6-
sulfonic) acid] (Roche) and stopped after 1 h with 1%
SDS. Absorbance at 405 nm was measured in a microplate
reader (Multiskan Ex, Labsystems). Titration of 2L21 and
VP2-specific IgG antibodies in rabbits was carried out as
mentioned above, but this time an anti-rabbit–IgG horse-
radish peroxidase whole antibody (BioSys, France) was
used. Titers were expressed as the highest serum dilution to
yield twice the absorbance mean of preimmune sera.
To determine IgG1 and IgG2a isotypes, plates coated with
2L21 peptide were incubated with serial dilutions of pooled
sera followed by biotin anti-mouse IgG1 and IgG2a.
Subsequently, plates were developed as mentioned above.
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standard curves constructed by coating wells with anti-Ig
antibody against the appropriate isotype and adding IgG
standards of the pertinent isotype. All coating, standards and
biotin antibodies were from BD Biosciences (Heidelberg,
Germany).
To determine the IgA antibodies induced after oral and
combined administration, plates coated with 2L21 peptide
were incubated with serial dilutions of pooled sera followed
by biotin anti-mouse IgA (Sigma). The concentration of IgA
was estimated using standard curves constructed by coating
wells with anti-IgA antibody (Sigma) and adding IgA
standards (Zymed, USA).
Sera and standards were always assayed by duplicate.
The antibody titers in individual sera were well represented
by the titer of the corresponding pooled serum.
Evaluation of antibody specificity by competitive ELISA
The specificity of VP2 recognition by sera elicited with
plant-derived CTB-2L21 was confirmed by competitive
ELISA. Pooled sera (day 50) from mice immunized with
CTB-2L21-enriched or -crude extracts were co-incubated
with 2-fold serial dilutions (0.1–100 AM) of soluble 2L21
peptide (1 h at 37 -C) before addition to the wells coated
with VP2 (0.1 Ag/well). The two sera were tested at
equivalent dilution (1/1000 and 1/70 for sera elicited with
CTB-2L21-enriched or -crude extracts, respectively). Equiv-
alent dilution is defined as the dilution at which both sera
showed similar optical density (OD) for the recognition of
the 2L21 peptide, this OD being in the linear section of the
anti-2L21 titration curve. As control, a parallel competitive
ELISA was carried out by pre-incubation of sera with serial
dilutions of plant-soluble proteins (0.1–50 ng/Al). Plates
were washed and developed as mentioned above. Sera were
assayed by duplicate. IC50 was defined as the concentration
(AM) of soluble 2L21 peptide at which the percentage of
inhibition of VP2 recognition is 50%.
Determination of antibodies against CTB and plant-soluble
proteins
The specificity of anti-sera to the carrier protein (CTB)
and plant-soluble proteins co-existing in the leaf extract was
determined by Western blot. Briefly, bacterial CTB (1 Ag),
CTB-2L21-enriched and -crude extracts and leaf extracts
from non-transformed plants were resolved on 10% SDS-
PAGE under reducing conditions. The amount of TSP
loaded in each lane was selected to get a similar blot
intensity corresponding to the CTB-2L21 bands. Resolved
proteins were transferred to nitrocellulose membrane
(Hybond, Amersham) and incubated with sera elicited with
CTB-2L21-enriched or -crude extracts at equivalent dilution
(1/1000 and 1/70, respectively). Reaction was developed
with a goat anti-mouse–IgG whole antibody horseradish
peroxidase conjugate (1/10000 diluted, Sigma) and the ECLWestern blotting system (Amersham). Chemiluminescence
was visualized using a gel documentation system (Chemi-
Doc, Bio-Rad).
In vitro neutralization assay
Neutralizing activity of the sera was determined by
assaying CPVinfection neutralizing assays on Crandell feline
kidney (CRFK) cells. VR-953 CPV strain was kindly
provided by Carmen Vela (Ingenasa), and CRFK cell lines
were obtained from the ATCC. CPV stock had a hemaggluti-
nation (HA) titer of 1024 (assay performed with 1% pig
erythrocytes, pH 7.0) (Carmichael et al., 1980). For the
neutralization assay, CPV was diluted to contain 10 HA
units. CRFK cells were grown in DMEM (Gibco) supple-
mented with 5% fetal calf serum (FCS, Gibco) at 37 -C in a
5% CO2 atmosphere. One day before the assay, CRFK cells
were seeded into 24-well culture plates at a concentration of
5  104 cells per well. The serum samples to be tested were
inactivated at 56 -C for 30 min. Several dilutions of sera
(5-fold serial dilutions in the case of the rabbit serum and 10-
fold serial dilutions in the case of mAb 3C9) were mixed
with CPV and incubated for 2 h (37 -C), previously to the
incubation with CRFK cells (37 -C, 5% CO2, 90 min). Then,
the mixture was removed, and fresh medium was added.
After 3 days of incubation, cells were fixed with methanol,
and infected cells were detected with mAb 3C9 and FITC-
conjugated anti-mouse IgG whole molecule (Sigma). Once
the fluorescent cells were counted, the infectivity percentage
was obtained as the ratio between the number of fluorescent
cells for a certain serum dilution and the number of
fluorescent cells for a control serum, multiplied by 100.
Neutralization percentage was calculated as 100 minus the
infectivity percentage. Five independent assays were per-
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